PRESS RELEASE published on 02/01/2024 at 12:30, 1 year 2 months ago Immunic to Participate in Investor and Scientific Conferences in February Immunic, Inc. (Nasdaq: IMUX) to participate in BioCapital Europe 2024 and ACTRIMS Forum 2024 in February and March, presenting clinical pipeline therapies and poster presentations Immunic, Inc. BioCapital Europe 2024 ACTRIMS Forum 2024 Clinical Pipeline Therapies Poster Presentations
PRESS RELEASE published on 11/02/2023 at 11:30, 1 year 5 months ago Immunic Receives Notice of Allowance for United States Patent Protecting the Treatment of Relapsing Multiple Sclerosis with Vidofludimus and Its Salts
PRESS RELEASE published on 10/26/2023 at 12:30, 1 year 5 months ago Immunic to Participate in Scientific and Industry Conferences in November
PRESS RELEASE published on 10/16/2023 at 12:30, 1 year 5 months ago Immunic Presents Data From Phase 2 CALDOSE-1 Trial of Vidofludimus Calcium in Ulcerative Colitis at the United European Gastroenterology Week 2023
PRESS RELEASE published on 10/15/2023 at 12:30, 1 year 5 months ago Immunic Presents Data From Phase 1b Clinical Trial of IMU-856 in Celiac Disease at the United European Gastroenterology Week 2023
PRESS RELEASE published on 10/11/2023 at 12:30, 1 year 5 months ago Immunic Presents Data From Phase 2 EMPhASIS Trial of Vidofludimus Calcium in Relapsing-Remitting Multiple Sclerosis at MSMilan2023: The 9th Joint ECTRIMS-ACTRIMS Meeting
PRESS RELEASE published on 10/09/2023 at 22:01, 1 year 5 months ago Immunic Reports Positive Interim Data from Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis
PRESS RELEASE published on 10/04/2023 at 12:30, 1 year 6 months ago Immunic to Participate in Scientific Conferences in October
PRESS RELEASE published on 09/06/2023 at 12:30, 1 year 7 months ago Immunic to Participate in Industry and Investor Conferences in September
PRESS RELEASE published on 08/17/2023 at 12:30, 1 year 7 months ago Immunic Completes Enrollment of Its Phase 2 CALLIPER Trial of Vidofludimus Calcium in Progressive Multiple Sclerosis
Published on 04/07/2025 at 14:30, 13 minutes ago Newsmax Enters into Standby Equity Purchase Agreement of Up to $1.2 Billion With Yorkville Advisors
Published on 04/07/2025 at 14:30, 13 minutes ago Sparta Provides Update on Delay in Filing Annual Financial Statements
Published on 04/07/2025 at 14:00, 43 minutes ago NOA Lithium Advances Towards 2025 Water Exploration at Rio Grande Project
Published on 04/07/2025 at 14:00, 43 minutes ago Rio Grande Resources Announces the Successful Completion of Sampling and Field Campaign at the Winston Gold-Silver Project
Published on 04/07/2025 at 14:00, 43 minutes ago Tharimmune Announces Positive Data with Novel Biparatopic PD-1/VEGF and Multispecific HER2/HER3 Biologics Leveraging Proprietary EpiClick(TM) Technology
Published on 04/07/2025 at 14:24, 18 minutes ago OTRS AG: Voluntary Public Tender Offer of Optimus BidCo AG
Published on 04/07/2025 at 13:00, 1 hour 43 minutes ago CureVac Receives U.S. FDA IND Clearance to Initiate Phase 1 Clinical Trial for Novel mRNA-Based Precision Immunotherapy in Squamous Non-Small Cell Lung Cancer
Published on 04/07/2025 at 12:57, 1 hour 45 minutes ago PFISTERER acquires long-standing partner Power CSL - portfolio expanded to include subsea solutions
Published on 04/07/2025 at 11:57, 2 hours 45 minutes ago Share buyback: Announcement pursuant to Article 5 (1) (b) and (3) of Regulation (EU) No. 596/2014
Published on 04/07/2025 at 07:01, 7 hours 42 minutes ago bioMérieux obtient le marquage CE pour LUMED™ APSS™, une solution logicielle de pointe pour aider à prendre des décisions en matière de bon usage des antibiotiques
Published on 04/07/2025 at 07:01, 7 hours 42 minutes ago bioMérieux obtains CE-marking for LUMED™ APSS™, a cutting-edge software solution to aid medical decision-making in Antimicrobial Stewardship
Published on 04/04/2025 at 19:18, 2 days 19 hours ago Mersen: Number of shares and voting rights as of March 31, 2025
Published on 04/04/2025 at 19:18, 2 days 19 hours ago Mersen : nombre d'actions et de droits de vote au 31 mars 2025
Published on 04/04/2025 at 18:17, 2 days 20 hours ago Reporting on share buyback transactions carried out between March 31 and April 3, 2025
